ALXN Insider Trading Activity and SEC Form 4 Filings
ALXN insider trading summary
No open-market insider purchases or sales of Alexion Pharmaceuticals, Inc. (ALXN) have been reported on SEC Form 4 in the past 12 months.
Latest ALXN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 17, 2020 | Daniel Bazarko | SVP, Controller, CAO | Sell | $174K (1,100 @ $158.00) |
| Dec 17, 2020 | Daniel Bazarko | SVP, Controller, CAO | Sell | $2.1M (13,066 @ $157.76) |
| Dec 17, 2020 | Daniel Bazarko | SVP, Controller, CAO | Sell | $1.6M (9,900 @ $157.59) |
| Dec 3, 2020 | Tanisha Carino | EVP & Ccao | Sell | $187K (1,530 @ $122.26) |
| Jun 8, 2020 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | $621K (5,420 @ $114.61) |
| Jun 8, 2020 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | $165K (1,433 @ $115.00) |
| Mar 18, 2020 | Baker Bros. Advisors LP | Director | Buy | $94K (1,158 @ $81.09) |
| Mar 18, 2020 | Baker Bros. Advisors (GP) LLC | Director | Buy | $94K (1,158 @ $81.09) |
| Mar 18, 2020 | Baker Bros. Advisors LP | Director | Buy | $1.0M (12,815 @ $81.09) |
| Mar 18, 2020 | Baker Brothers Life Sciences LP | Director | Buy | $94K (1,158 @ $81.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.